Crockett Thomas Andrew's most recent trade in KalVista Pharmaceuticals Inc was a trade of 54,415 Common Stock done . Disclosure was reported to the exchange on Feb. 17, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| KalVista Pharmaceuticals Inc | Crockett Thomas Andrew | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 54,415 | 236,091 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Crockett Andrew Thomas | Director, CEO | Sale of securities on an exchange or to another person at price $ 14.11 per share. | 17 Feb 2024 | 24,888 | 211,203 (1%) | 0% | 14.1 | 351,289 | Common Stock |
| KalVista Pharmaceuticals Inc | Andrew Crockett Thomas | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 20,833 | 20,834 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Crockett Thomas Andrew | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 20,833 | 62,500 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Andrew Thomas Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 6,944 | 48,612 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Crockett Andrew Thomas | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2024 | 5,805 | 52,245 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Crockett Thomas Andrew | Director, CEO | Sale of securities on an exchange or to another person at price $ 15.01 per share. | 14 Feb 2024 | 58,356 | 181,676 (1%) | 0% | 15.0 | 875,883 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2024 | 122,500 | 240,032 (1%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Crockett Andrew Thomas | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2024 | 83,333 | 83,333 | - | - | Performance Stock Units | |
| KalVista Pharmaceuticals Inc | Andrew Thomas Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 16.18 per share. | 01 Feb 2024 | 9,300 | 118,232 (0%) | 0% | 16.2 | 150,428 | Common Stock |
| KalVista Pharmaceuticals Inc | Andrew Crockett Thomas | Director, CEO | Sale of securities on an exchange or to another person at price $ 16.81 per share. | 01 Feb 2024 | 700 | 117,532 (0%) | 0% | 16.8 | 11,770 | Common Stock |
| KalVista Pharmaceuticals Inc | Crockett Andrew Thomas | Director, CEO | Sale of securities on an exchange or to another person at price $ 12.02 per share. | 27 Dec 2023 | 30,000 | 127,532 (0%) | 0% | 12.0 | 360,453 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 33,582 | 161,632 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 20,833 | 0 | - | - | Performance Stock Unit | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 10.73 per share. | 17 Aug 2023 | 14,876 | 146,756 (0%) | 0% | 10.7 | 159,602 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 6,944 | 62,501 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2023 | 5,805 | 63,855 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2023 | 6,944 | 76,390 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2022 | 5,805 | 116,663 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2022 | 5,805 | 81,270 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 5.44 per share. | 17 Nov 2022 | 1,785 | 114,878 (0%) | 0% | 5.4 | 9,710 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 02 Sep 2022 | 6,500 | 112,178 (0%) | 0% | 0 | Common Stock | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 17.01 per share. | 02 Sep 2022 | 1,320 | 110,858 (0%) | 0% | 17.0 | 22,458 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2022 | 5,805 | 91,083 | - | - | Restricted Stock Unit | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Aug 2022 | 5,805 | 113,975 (0%) | 0% | - | Common Stock | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 14.96 per share. | 17 Aug 2022 | 1,797 | 112,178 (0%) | 0% | 15.0 | 26,890 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 92,880 | 92,880 | - | - | Restricted Stock Units | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 61,920 | 61,920 | - | - | Employee Stock Option (Right to Buy) | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 17.07 per share. | 09 Mar 2022 | 10,000 | 114,670 (0%) | 0% | 17.1 | 170,693 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 17.18 per share. | 01 Oct 2021 | 10,000 | 124,670 (0%) | 0% | 17.2 | 171,841 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 24.35 per share. | 01 Jul 2021 | 5,650 | 134,670 (0%) | 0% | 24.4 | 137,605 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 23.88 per share. | 01 Jul 2021 | 4,350 | 140,320 (0%) | 0% | 23.9 | 103,872 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 17 Jun 2021 | 1,067 | 144,670 (0%) | 0% | 30.0 | 32,051 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2021 | 200,000 | 200,000 | - | - | Employee Stock Option (Right to Buy) | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 May 2021 | 4,750 | 154,670 (0%) | 0% | 0 | Common Stock | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 27.48 per share. | 01 Apr 2021 | 8,500 | 160,220 (0%) | 0% | 27.5 | 233,590 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 28.11 per share. | 01 Apr 2021 | 800 | 159,420 (0%) | 0% | 28.1 | 22,490 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 26.22 per share. | 01 Apr 2021 | 700 | 168,720 (0%) | 0% | 26.2 | 18,356 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 33.73 per share. | 23 Feb 2021 | 7,218 | 171,702 (0%) | 0% | 33.7 | 243,430 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 32.94 per share. | 23 Feb 2021 | 1,575 | 170,127 (0%) | 0% | 32.9 | 51,877 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 31.87 per share. | 23 Feb 2021 | 707 | 169,420 (0%) | 0% | 31.9 | 22,531 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 35.40 per share. | 23 Feb 2021 | 500 | 178,920 (1%) | 0% | 35.4 | 17,700 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2021 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2021 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.13 per share. | 04 Jan 2021 | 9,186 | 186,234 (1%) | 0% | 18.1 | 166,558 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 04 Jan 2021 | 6,000 | 179,420 (1%) | 0% | 0 | Common Stock | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.85 per share. | 04 Jan 2021 | 814 | 185,420 (1%) | 0% | 18.9 | 15,346 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.51 per share. | 20 Oct 2020 | 13,052 | 199,113 (1%) | 0% | 18.5 | 241,641 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 17.27 per share. | 20 Oct 2020 | 11,218 | 222,741 (1%) | 0% | 17.3 | 193,786 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 17.48 per share. | 20 Oct 2020 | 5,800 | 212,165 (1%) | 0% | 17.5 | 101,412 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 20 Oct 2020 | 4,776 | 217,965 (1%) | 0% | 18.0 | 85,992 | Common Stock |
| KalVista Pharmaceuticals Inc | Thomas Andrew Crockett | Director, CEO | Sale of securities on an exchange or to another person at price $ 19.01 per share. | 20 Oct 2020 | 3,693 | 195,420 (1%) | 0% | 19.0 | 70,194 | Common Stock |